View 
FILTERS (0)
* Not connected to ResearchPool

MORE FILTERS

  
reports
Adam Karlsson ... (+3)
  • Adam Karlsson
  • Rickard Anderkrans
  • Viktor Sundberg

Powerpoint Sector Report - Swedish Biotech Monthly: September Issue

September 2021 edition of ABG Sundal Collier's monthly Biotech update. An overview of the newsflow in August and near-term milestones. An overview of our universe of Swedish Biotech stocks.

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Viktor Sundberg

Oncopeptides - ODAC meeting for Pepaxto coming up

FDA to convene on ODAC meeting on October 28 Release of briefing doc a new key trigger Net negative for the case

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Viktor Sundberg

Swedish Orphan Biovitrum - Formal bid for SOBI

SEK 235 bid from Advent and Aurora Unanimously recommended by SOBI’s board Investor and AP4 holding 43% have undertaken to accept

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Viktor Sundberg

PCI Biotech - Q2’21 Report

Slow RELEASE recruitment leading to readout delay Cash runway into H2’22 will necessitate raise before data Implications for the share

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Viktor Sundberg

Oncopeptides - The long voyage continues

OCEAN (and PORT) abstracts released ahead of IMW No details on sub-group OS data in abstract Maintain that confirmatory clinical trial data likely needed

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Viktor Sundberg

SynAct Pharma - Q2’21 Report

RA readout postponed to Q4’21 Financials Implications for the share

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Viktor Sundberg

Nordic Nanovector - Q2’21 Report

94 pts recruited to PARADIGME, readout shifted to H1’22 Financials Implications for the share

Adam Karlsson ... (+4)
  • Adam Karlsson
  • Jakob Lembke
  • Marit Olsen
  • Viktor Sundberg

Arctic Bioscience - Going in the right direction

Pharma on track and 51% growth in Nutra >40% growth outlook for ‘21e Reiterate BUY with SOTP-based TP of NOK 54 (57)

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Viktor Sundberg

Swedish Orphan Biovitrum - SOBI silly season

PE firms speculated to acquire Sobi Our take on these rumors A quick note on valuation

Erik Cassel ... (+3)
  • Erik Cassel
  • Johan Brown
  • Rickard Anderkrans

Vimian Group - Executing according to plan

Clear focus on expansion: 25% y-o-y organic growth Trimming our elevated estimates… …lowers our TP to SEK 108 (110) – reiterate HOLD

Marit Olsen ... (+3)
  • Marit Olsen
  • Rickard Anderkrans
  • Viktor Sundberg

Arctic Bioscience - Pharma develops according to plan

Sales below but adj. EBITDA in line Pharma business according to plan No major revisions expected

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Viktor Sundberg

AstraZeneca - A Phase 3 win in Wilson Disease

ALXN1840 met primary endpoint in Ph3 FoCus trial A positive data point out of the Alexion acquisition ~USD 250m peak sales could be in the cards

Adam Karlsson ... (+3)
  • Adam Karlsson
  • Rickard Anderkrans
  • Viktor Sundberg

Saniona - Q2’21 Report

SAN711 entering clinical development Financials Implications for the share

Johan Brown ... (+2)
  • Johan Brown
  • Rickard Anderkrans

Vimian Group - A clear focus on driving growth

Q2: 25% organic growth, adj. EBITA -9% vs cons Recent M&A likely to mitigate slight negative revisions High expectations could pressure shares today

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Viktor Sundberg

Nanexa AB - Q2’21 Report

Important events during and after the quarter Financials Implications for the share

Adam Karlsson ... (+3)
  • Adam Karlsson
  • Rickard Anderkrans
  • Viktor Sundberg

Ultimovacs - Q2’21 Report

Clinical trial updates and other news Financials Implications for the share

Jakob Lembke ... (+2)
  • Jakob Lembke
  • Viktor Sundberg

Humana - Strong Q2’21 report

Organic growth of 3.4% and adj. EBIT margin of 5.2% Consensus EBIT estimates could come up with 6% Conference call at 09:00 CET

Adam Karlsson ... (+3)
  • Adam Karlsson
  • Rickard Anderkrans
  • Viktor Sundberg

Immunovia AB - Q2’21 report

Recent developments during and after the quarter Financials Share price implication

Adam Karlsson ... (+2)
  • Adam Karlsson
  • Viktor Sundberg

Egetis Therapeutics - Q2’21 Report

TRIAC II on-track, Emcitate demand growing Financials Implications for the share

Rickard Anderkrans ... (+2)
  • Rickard Anderkrans
  • Viktor Sundberg

BICO Group - Growth demands change

Impressive 36% sales beat with 95% organic growth Raising ’21e-‘23e sales by 6-1%, cutting EBITDA by ~5% New TP of SEK 610 (SEK 640) – keeping BUY

Loading...
New interest

Save your current filters as a new Interest

Please enter a name for this interest

Email alerts

Would you like to receive real-time email alerts when a new report is published under this interest?

Save This Search

These search results will show up under 'Saved searches' in the left panel

Please enter a name for this saved search

ResearchPool Subscriptions

Get the most out of your insights

Get in touch